Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|December 5, 2020
Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphomaGa-Young Song, Dok Hyun Yoon, Cheolwon Suh, et al.
Annals of Hematology|January 24, 2024
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysisJun Ho Yi, Sung-Soo Park, Chang-Ki Min, et al.
World Journal of Gastroenterology|February 17, 2015
Retrospective analysis of extra-gastrointestinal stromal tumorsJun Ho Yi, Byeong-Bae Park, Jung Hun Kang, et al.
Molecular Cancer Therapeutics|August 25, 2011
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapySeung Tae Kim, Do Hyoung Lim, Kee-Taek Jang, et al.
Cancer Research and Treatment|July 3, 2025
A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)Kwai Han Yoo, Sang Eun Yoon, Ka-Won Kang, et al.
Expert Opinion on Biological Therapy|February 9, 2023
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of KoreaJae-Cheol Jo, Youngwoo Jeon, DaJung Kim, et al.
British Journal of Haematology|November 28, 2025
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 16, 2023
Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 StudyJun Ho Yi, Jung Lim Lee, Yoo Jin Lee, et al.
Cancer Research and Treatment|November 10, 2023
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in KoreaJi Yun Lee, Ji Hyun Kwon, Joon Young Hur, et al.
Oncology|June 25, 2011
A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancerJun Ho Yi, Jeeyun Lee, Se Hoon Park, et al.
Pageof 7